immunotherapy in lung cancer

سال انتشار: 1403
محل انتشار: دومین کنگره بین المللی کنسرژنومیکس
کد COI اختصاصی: ICGCS02_503
زبان مقاله: انگلیسی
تعداد مشاهده: 76

نویسندگان

Department of Biology,Faculty of Nano and Bio Science and Technology, Persian Gulf University

چکیده

Lung cancer is amongst the most pervasive malice having high mortality rates. Lung cancer is considerably grouped intonon-small-cell lung cancer ( NSCLC) and small- cell lung cancer( SCLC). medicinal options for lung cancer treatment include surgery, radiation remedy, chemotherapy, and targeted medicine remedy. Medical operation is continually associated with the development of treatment resistance leading to relapse. Immunotherapy is profoundly altering the approach to cancer treatment owing to its tolerable safety profile, sustained remedial response due to immunological memory generation, and effectiveness across a broad patient population. The conception of individualized drug has overshadowed the conventional chemotherapy given to all cases with lung cancer. The targeted remedy is given to a particular population having specific mutations to help in the better operation of lung cancer. The targeting pathways for NSCLC include the epidermal growth factor receptor, vascular endothelial growth factor receptor, MET ( Mesenchymal epithelial transition factor) oncogene, Kirsten rat sarcoma viral oncogene( KRAS), and anaplastic carcinoma kinase( ALK). SCLC targeting pathway includes Poly( ADP- ribose) polymerases( PARP) impediments, checkpoint kinase ۱( CHK ۱) pathway, WEE۱ pathway, Ataxia Telangiectasia and Rad۳- related( ATR)/ Ataxia telangiectasia changed( ATM), and Delta ‐ like canonical Notch ligand ۳( DLL- Immune checkpoint impediments like programmed cell death protein ۱( PD- ۱)/ programmed death- ligand ۱( PD- L۱) impediments and Cytotoxic T- lymphocyte- associated antigen- ۴( CTLA۴) leaguer are also employed in the operation of lung cancer. numerous of the targeted curatives are still under development and bear clinical trials to establish their safety and efficacity. This review summarizes the medium of molecular targets and vulnerable- mediated targets, lately approved medicines, and their clinical trials for lung cancer. also, the review also explores the recrimination of nanomedicine in lung cancer immunotherapy as well as the combinatorial operation of traditional remedy along with immunotherapy rules. Eventually, ongoing clinical trials, significant obstacles, and the unborn outlook of this treatment strategy are also emphasized to boost farther exploration in the field.

کلیدواژه ها

immunotherapy, lung cancer, antibody, nanomedicine

مقالات مرتبط جدید

اطلاعات بیشتر در مورد COI

COI مخفف عبارت CIVILICA Object Identifier به معنی شناسه سیویلیکا برای اسناد است. COI کدی است که مطابق محل انتشار، به مقالات کنفرانسها و ژورنالهای داخل کشور به هنگام نمایه سازی بر روی پایگاه استنادی سیویلیکا اختصاص می یابد.

کد COI به مفهوم کد ملی اسناد نمایه شده در سیویلیکا است و کدی یکتا و ثابت است و به همین دلیل همواره قابلیت استناد و پیگیری دارد.